
Neuro-focused start-up Biohaven nets $180mm in oversubscribed IPO on NYSE
Executive Summary
Deal Industry
- Biotechnology
- Pharmaceuticals
-
In Vitro Diagnostics
- Therapeutic Drug Monitoring
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com